Literature DB >> 14602367

In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum.

J Sánchez Hernández1, B Mora Peris, G Yagüe Guirao, N Gutiérrez Zufiaurre, J L Muñoz Bellido, M Segovia Hernández, J A García Rodríguez.   

Abstract

The in vitro activity of ciprofloxacin, erythromycin, telithromycin, teicoplanin, linezolid and quinupristin-dalfopristin was tested against human derived pathogenic corynebacteria. The MICs of these antibiotics were measured using the agar dilution method against 31 strains of Corynebacterium jeikeium, 58 Corynebacterium amycolatum (including 33 multidrug-resistant strains) and 64 Corynebacterium urealyticum clinical strains. A high resistance rate to ciprofloxacin and erythromycin was found in the three species. Telithromycin was much more active than erythromycin (MIC(90) of erythromycin >or=128 mg/l for all three species; MIC(90) of telithromycin: 4 mg/l for C. jeikeium, 64 mg/l for C. amycolatum and 1 mg/l for C. urealyticum). There were no teicoplanin-resistant (MIC(90) 1, 0.5 and 1 mg/l, respectively) or linezolid-resistant strains (MIC(90) 1, 0.2 and 0.5 mg/l, respectively). Quinupristin-dalfopristin was active against most strains with an activity similar to linezolid, but three C. jeikeium and one C. amycolatum showed MICs >or=4 mg/l. Telithromycin showed much better activity against corynebacteria than older macrolides. Synercid and linezolid were active against most isolates tested, including multidrug resistant strains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602367     DOI: 10.1016/s0924-8579(03)00121-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  In vitro activity of quinupristin and dalfopristin in combination and alone against coryneform bacteria.

Authors:  G Funke; R Troxler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

2.  Minimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteria.

Authors:  G Funke; C Nietznik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

Review 3.  A case report and literature review of Corynebacterium urealyticum infection acquired in the hospital.

Authors:  Giuseppe Famularo; Giovanni Minisola; Giulio Cesare Nicotra; Gabriella Parisi; Claudio De Simone
Journal:  Intern Emerg Med       Date:  2008-02-12       Impact factor: 3.397

4.  Successful treatment of Corynebacterium urealyticum encrusting cystitis with systemic and intravesical antimicrobial therapy.

Authors:  Oriana Raab; Romain Béraud; Karen M Tefft; C Anne Muckle
Journal:  Can Vet J       Date:  2015-05       Impact factor: 1.008

Review 5.  Corynebacterium jeikeium endocarditis: a systematic overview spanning four decades.

Authors:  F Mookadam; M Cikes; L M Baddour; I M Tleyjeh; M Mookadam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

Review 6.  Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract.

Authors:  Kimberly A Kline; Amanda L Lewis
Journal:  Microbiol Spectr       Date:  2016-04

7.  Corynebacterium Species Rarely Cause Orthopedic Infections.

Authors:  Fabian Kalt; Bettina Schulthess; Reinhard Zbinden; Yvonne Achermann; Fabian Sidler; Sebastian Herren; Sandro F Fucentese; Patrick O Zingg; Martin Berli; Annelies S Zinkernagel
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

8.  Clinical characteristics and drug susceptibility patterns of Corynebacterium species in bacteremic patients with hematological disorders.

Authors:  Masahiro Abe; Muneyoshi Kimura; Hideyuki Maruyama; Tomohisa Watari; Sho Ogura; Shinsuke Takagi; Naoyuki Uchida; Yoshihito Otsuka; Shuichi Taniguchi; Hideki Araoka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-24       Impact factor: 3.267

Review 9.  Corynebacterium urealyticum: a comprehensive review of an understated organism.

Authors:  Nagla Salem; Lamyaa Salem; Sally Saber; Ghada Ismail; Martin H Bluth
Journal:  Infect Drug Resist       Date:  2015-05-21       Impact factor: 4.003

Review 10.  Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.

Authors:  Els Van de Perre; Gina Reichman; Deborah De Geyter; Caroline Geers; Karl M Wissing; Emmanuel Letavernier
Journal:  Front Med (Lausanne)       Date:  2021-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.